OverviewSuggest Edit

Epidemiological studies suggest that over half of Americans are sensitive to at least one allergen. Environmental and lifestyle changes, urbanization, pollution, dietary changes, development of sanitation standards and decrease in chronic bacterial infections all are assumed to be factors promoting the rapid increase in prevalence of allergy throughout the developed world. Approximately 3% to 5% of Americans suffer from food allergies with a number of recent studies suggesting that approximately 8% of children have some type of food allergy. Recent studies suggest that patients with food allergies are especially at risk of experiencing significant disruption in their daily lives. Recent scientific studies suggest that treating allergies early in life could prevent disease progression or the development of polyallergies, however, no approved treatments currently exist for young allergic children.
TypePublic
Founded2002
HQMontrouge, FR
Websitedbv-technologies.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Jan 2017)113
Revenue (FY, 2018)€14.5 M(+23%)
Share Price (Sept 2019)$8.9 (-3%)

Key People/Management at DBV Technologies

Pierre-Henri Benhamou

Pierre-Henri Benhamou

CEO & CSO
David Schilansky

David Schilansky

CFO
Bertrand Dupont

Bertrand Dupont

CTO
Charles Ruban

Charles Ruban

CDO
Show more

DBV Technologies Office Locations

DBV Technologies has offices in Montrouge and New York
Montrouge, FR (HQ)
181 Avenue Pierre Brossolette
New York, US
320 Park Ave
Show all (2)

DBV Technologies Financials and Metrics

DBV Technologies Revenue

DBV Technologies's revenue was reported to be €14.54 m in FY, 2018
EUR

Revenue (FY, 2018)

14.5m

Net income (FY, 2018)

(166.1m)

EBIT (FY, 2018)

(166.2m)

Market capitalization (24-Sept-2019)

641.5m

Closing stock price (24-Sept-2019)

8.9

Cash (31-Dec-2018)

122.8m

EV

520.0m
DBV Technologies's current market capitalization is $641.5 m.
EURFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

6.2m9.1m11.9m14.5m

Revenue growth, %

47%31%

Cost of goods sold

128.0k

Gross profit

6.0m
EURFY, 2015FY, 2016FY, 2017FY, 2018

Cash

323.4m256.5m137.9m122.8m

Accounts Receivable

1.3m1.3m

Inventories

1.6m

Current Assets

334.9m272.2m156.9m145.5m
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(44.7k)(114.5k)(147.7k)(166.1m)

Depreciation and Amortization

1.1k1.3k2.9k

Accounts Payable

8.2k3.6k3.3k

Cash From Operating Activities

(26.8k)(59.5k)(114.3k)(136.6m)
EURY, 2018

EV/EBIT

-3.1 x

EV/CFO

-3.8 x

Financial Leverage

1.4 x
Show all financial metrics

DBV Technologies Online and Social Media Presence

Embed Graph

DBV Technologies News and Updates

DBV Technologies Frequently Asked Questions

  • When was DBV Technologies founded?

    DBV Technologies was founded in 2002.

  • Who are DBV Technologies key executives?

    DBV Technologies's key executives are Pierre-Henri Benhamou, David Schilansky and Bertrand Dupont.

  • How many employees does DBV Technologies have?

    DBV Technologies has 113 employees.

  • What is DBV Technologies revenue?

    Latest DBV Technologies annual revenue is €14.5 m.

  • What is DBV Technologies revenue per employee?

    Latest DBV Technologies revenue per employee is €128.6 k.

  • Who are DBV Technologies competitors?

    Competitors of DBV Technologies include Clementia Pharmaceuticals, Synthace and Cord Blood America.

  • Where is DBV Technologies headquarters?

    DBV Technologies headquarters is located at 181 Avenue Pierre Brossolette, Montrouge.

  • Where are DBV Technologies offices?

    DBV Technologies has offices in Montrouge and New York.

  • How many offices does DBV Technologies have?

    DBV Technologies has 2 offices.